Superluminal Medicines
Boston, United States · Biotechnology, Health Care · 29 employees
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
Funding history
- Funding Round — $5.0M — Aug 2025
- Series series a — $120.0M — Sep 2024
- Funding Round — $20.0M — Sep 2024
- Funding Round — $25.7M — Aug 2023
- Series seed — $33.0M — Aug 2023
Recent signals
- Aug 26, 2025: Raised $5.0M
- Sep 09, 2024: Raised $120.0M in Series series a
- Sep 09, 2024: Superluminal Medicines Secures $120 Million Series A Round for Clinical Development and Expansion of Small Molecule Pipeline
- Sep 04, 2024: Raised $20.0M
- Aug 28, 2023: Raised $25.7M
- Aug 28, 2023: Raised $33.0M in Series seed
See plans & pricing → Track Superluminal Medicines’s funding, hiring, and signals — with verified contacts — on Fundz.